SCHEMBL29974086

SCHEMBL29974086

CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)O)CCCN1C(=O)CCC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DNM1 Q05193 1/20 0.44
▸ DGKA P23743 1/20 0.43
▸ PAM P19021 2/20 0.41
▸ KDM5A P29375 2/20 0.41
▸ PHF8 Q9UPP1 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ RECQL P46063 2/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ PRSS1 P07477 1/20 0.40
▸ PRSS2 P07478 1/20 0.40
▸ PRSS3 P35030 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ PRKCA P17252 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18789580 0.95 DNM1 (0.48) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL18641652 0.86 ALDH1A1 (0.43) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632764 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632735 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632750 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632743 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632719 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632693 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL31632698 0.86 DGKA (0.56) DNM1DGKAMAPTRECQLL3MBTL1
SCHEMBL25626482 0.83 DGKA (0.59) DNM1DGKAPAMKDM5APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078082-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX INC (US) 2026-03-19 — — US disclosed
EP-4186888-B1 COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX INC (US) 2025-11-26 — — EP disclosed
EP-4286012-A2 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ModernaTX, Inc. (US) 2023-12-06 — — EP disclosed
EP-3736261-B1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX INC (US) 2023-10-11 — — EP disclosed
EP-4186888-A1 COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS ModernaTX, Inc. (US) 2023-05-31 — — EP disclosed
EP-3596041-B1 COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX INC (US) 2022-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078082-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS PHOSPHO1, LIPC, SDCBP DNM1 265/4885DGKA 239/4885PAM 1977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback